dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Federal de São Paulo (UNIFESP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorInstituto Fleury
dc.date.accessioned2014-05-27T11:22:28Z
dc.date.accessioned2022-10-05T18:07:04Z
dc.date.available2014-05-27T11:22:28Z
dc.date.available2022-10-05T18:07:04Z
dc.date.created2014-05-27T11:22:28Z
dc.date.issued2007-05-21
dc.identifierThrombosis Research, v. 120, n. 2, p. 221-229, 2007.
dc.identifier0049-3848
dc.identifierhttp://hdl.handle.net/11449/69670
dc.identifier10.1016/j.thromres.2006.09.015
dc.identifier2-s2.0-34248512217
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3919080
dc.description.abstractIntroduction: Venous thrombosis (VT) and inflammation are two closely related entities. In the present investigation we assessed whether there is a relation between genetic modifiers of the inflammatory response and the risk of VT. Materials and methods: 420 consecutive and unrelated patients with an objective diagnosis of deep VT and 420 matched controls were investigated. The frequencies of the following gene polymorphisms were determined in all subjects: TNF-α- 308 G/A, LT-α+ 252 A/G, IL-6-174 G/C, IL1-ra 86 bp VNTR, IL-10-1082 A/G and CD-31 125 C/G. Results: Overall odds ratio (OR) for VT related to TNF-α- 308 G/A, LT-α+ 252 A/G, IL-6-174 G/C, A1 allele (4 bp repeat) of the IL1-ra 86 bp VNTR, IL-10-1082 A/G and CD-31 125 C/G were respectively: 1.0 (CI95: 0.8-1.5), 1.3 (CI95: 1.0-1.7), 1.1 (CI95: 0.9-1.5), 1.6 (CI95: 1-2.5), 1.2 (CI95: 0.8-1.7) and 0.8 (CI95: 0.6-1.1). A possible interaction between polymorphisms was observed only for the co-inheritance of the mutant alleles of the LT-α+ 252 A/G and IL-10-1082 G/A polymorphisms (OR = 2; CI95: 1.1-3.8). The risk of VT conferred by factor V Leiden and FII G20210A was not substantially altered by co-inheritance with any of the cytokine gene polymorphisms. Conclusions: Cytokine gene polymorphisms here investigated did not significantly influence venous thrombotic risk. © 2006 Elsevier Ltd. All rights reserved.
dc.languageeng
dc.relationThrombosis Research
dc.relation2.779
dc.relation1,096
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectCoagulation
dc.subjectCytokines
dc.subjectInflammation
dc.subjectPolymorphisms
dc.subjectThrombosis
dc.subjectVenous thromboembolism
dc.subjectblood clotting factor 11
dc.subjectblood clotting factor 5 Leiden
dc.subjectCD31 antigen
dc.subjectcytokine
dc.subjectinterleukin 1 receptor blocking agent
dc.subjectinterleukin 10
dc.subjectinterleukin 6
dc.subjectlymphotoxin
dc.subjecttumor necrosis factor alpha
dc.subjectcardiovascular risk
dc.subjectdeep vein thrombosis
dc.subjectgenetic polymorphism
dc.subjectinflammation
dc.subjectmajor clinical study
dc.subjectmedical research
dc.subjectBase Sequence
dc.subjectCase-Control Studies
dc.subjectDNA Primers
dc.subjectInterleukin 1 Receptor Antagonist Protein
dc.subjectInterleukin-10
dc.subjectInterleukin-6
dc.subjectLymphotoxin-alpha
dc.subjectMiddle Aged
dc.subjectOdds Ratio
dc.subjectPolymorphism, Genetic
dc.subjectTumor Necrosis Factor-alpha
dc.subjectVariation (Genetics)
dc.subjectVenous Thrombosis
dc.titleCytokine gene variants and venous thrombotic risk in the BRATROS (BRAZILIAN THROMBOSIS STUDY)
dc.typeArtigo


Este ítem pertenece a la siguiente institución